We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Email registered. Please sign in.×
Enter your contact to build trust with supplier(s)×
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Founded in 2000, Hainan Shuangcheng Pharmaceuticals Co., Ltd (HNSP) is a publicly-traded company and engaged in development, manufacturing and marketing of both APIs and drug products. Having excellent know-how in peptide chemistry, HNSP is a leader in the field of peptide manufacture, with current U.S. FDA and AIFA (Italian Medicines Agency) approved production.
The company is headquartered near Haikou airport on Hainan Island, China with R&D and manufacturing facilities at the Haikou site, and is building new facilities in Ningbo, about 1.5 hours’ drive from Shanghai’s Pudong Airport (PVG). HNSP also has a subsidiary company in Italy.
HNSP is rapidly expanding in China and elsewhere around the world, and is presently seeking collabrations and partnership with pharmaceutical companies in the U.S., Europe and other regions.
Main Competitive Advantages: International Approvals/Standards,Experienced R&D Staff,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Quality Service
Other Competitive Advantages:
Patents and Copyrights:
Business Type: Manufacturer
R&D capacity: Own Brand
Annual Turnover(USD):
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Middle East
Two years of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
